August 26, 2015 - ZOLL LifeVest Wearable Defibrillator and Temperature Management Solutions to Be Showcased at ESC Congress 2015


Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
[email protected]


August 26, 2015—CHELMSFORD, MASS.—ZOLL® Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it will display the LifeVest® Wearable Defibrillator along with sudden cardiac death (SCD) education and screening tools, the Thermogard XP® Temperature Management System, and the LifeBridge® system in Booth D600 at the European Society of Cardiology Congress 2015, 29 August–2 September in London.

The LifeVest will be discussed during the following scientific sessions:

  • A satellite symposium entitled “Remote Patient Management: Protecting Patients with the Wearable Cardioverter Defibrillator” will be chaired by Prof. Dr. Gerhard Hindricks, Heart Center Leipzig, Germany, and Prof. Dr. Hans-Peter Brunner-La Rocca, University Hospital Maastricht, Netherlands. It will be presented by Prof. Dr. Philippe Mabo, University Hospital Rennes, France, and Prof. Dr. Dierk Thomas, University Hospital Heidelberg, Germany, Monday, 31 August, 13-13:45, Tunis-Village 7.
  • Dr. Nadine Waessnig, Dresden University of Technology, Dresden, Germany, will present “German National Experience with the Wearable Cardioverter-Defibrillator (WCD),” Sunday, 30 August, 11:27, Agora-Poster Area, Poster #1323.
  • Dr. Helmut Klein, Isar Heart Center, Munich, Germany, will present “Wearable Cardioverter-Defibrillator,” Sunday, 30 August, 12:07, Algiers-Village 4, Poster #1244.
  • Dr. Victoria Johnson, University of Giessen, Germany, will present “Arrhythmia Treatment and Survival of Patients Wearing the Cardioverter Defibrillator Vest,” Tuesday, 1 September, 16:04, Moderated Poster Area, Poster #P5928.

The LifeVest protects patients at risk for SCD. It is used for a wide range of patient conditions or situations, including following a myocardial infarction, before or after coronary revascularization, and for those with cardiomyopathy or congestive heart failure that places them at particular risk. The LifeVest gives physicians time to optimize medical therapy and assess a patient’s long-term risk for sudden death.

In the WEARIT-II prospective registry of 2,000 patients prescribed the LifeVest, the sustained VT/VF event rate was high with 22 events per 100 patient-years—2.1% of patients had a VT/VF event.1 One in 14 patients experienced a clinically meaningful arrhythmia requiring intervention while wearing the LifeVest.1 The LifeVest Network online patient management system provides customizable tools for physicians and clinicians to access these captured arrhythmias, like atrial fibrillation or non-sustained ventricular tachyarrhythmias, and determine the appropriate intervention.

The LifeVest is lightweight and easy to wear, allowing patients to return to their common activities of daily living, while having the peace of mind that they are protected from SCD. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

The Thermogard XP (TGXP) System provides precise, effective therapy for every protocol and every patient. Patients reach target temperature quickly and accurately with TGXP.2,3 A variety of standard central venous catheters enables the treatment to be tailored to the individual.

The LifeBridge System allows the cardiovascular system and critical organs to rest, heal, and recover by improving blood flow and oxygenation in an emergency setting.

About ZOLL Medical Corporation

ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, therapeutic temperature management, and ventilation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care. For more information, visit

About Asahi Kasei

The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 30,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit

11Kutyifa V, et al. Results from the Prospective Registry of Patients Using the Wearable Defibrillator (WEARIT-II Registry), presented as Late Breaking Clinical Trial at the European Society of Cardiology Congress, September 3, 2014.
2Mayer SA, et al. Critical Care Medicine. 2004;(3)212:2508-2515.
3Diringer MN, et al. Critical Care Medicine. 2004;(32)2:559-564.

Copyright © 2015 ZOLL Medical Corporation. LifeBridge, LifeVest, Thermogard XP, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All product names are the property of their respective owners.